NCT03378427View on ClinicalTrials.gov

Tedizolid Prolonged Treatment for Prosthetic Joint Infections

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 28, 2018

Primary Completion Date

October 22, 2020

Study Completion Date

August 22, 2021

Conditions
Prosthetic Joint Infection
Interventions
DRUG

Tedizolid Phosphate 200 MG [Sivextro]

Antibiotic treatment (monotherapy or combination) targeting bacteria cultured from per operative samples.

Trial Locations (2)

69004

Hôpital de la Croix Rousse, Lyon

92380

Hôpital Ambroise Paré, Boulogne-Billancourt

All Listed Sponsors
collaborator

Eric SENNEVILLE M.D. Ph.D.

UNKNOWN

lead

Tourcoing Hospital

OTHER

NCT03378427 - Tedizolid Prolonged Treatment for Prosthetic Joint Infections | Biotech Hunter | Biotech Hunter